TECTONIC THERAPEUTIC, INC. Earnings Per Share (Basic)
TECTONIC THERAPEUTIC, INC. (TECX) reported Earnings Per Share (Basic) of -$1.18 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- TECTONIC THERAPEUTIC, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$1.18.
- TECTONIC THERAPEUTIC, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$1.34.
- TECTONIC THERAPEUTIC, INC. earnings per share, basic for the quarter ending 2025-12-31 was -$1.03.
- TECTONIC THERAPEUTIC, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$1.02.
- TECTONIC THERAPEUTIC, INC. earnings per share, basic for fiscal 2025 was -$4.05.
- TECTONIC THERAPEUTIC, INC. earnings per share, basic for fiscal 2024 was -$6.83.
- TECTONIC THERAPEUTIC, INC. earnings per share, basic for fiscal 2023 was -$33.76.
- TECTONIC THERAPEUTIC, INC. earnings per share, basic for fiscal 2022 was -$2.42.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.18 10-Q · filed 2026-08-06 | -$2.52 10-Q · filed 2026-08-06 | -$3.55 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$4.57 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||||
| 2026-03-31 | -$1.34 10-Q · filed 2026-05-07 | -$2.37 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$3.39 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$4.46 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||||
| 2025-12-31 | -$1.03 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$2.04 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$3.11 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$4.05 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | -$1.02 10-Q · filed 2025-11-06 | -$2.09 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$3.02 10-Q · filed 2025-11-06 | -$3.88 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||||
| 2025-06-30 | -$1.07 10-Q · filed 2026-08-06 | -$2.00 10-Q · filed 2026-08-06 | -$2.86 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$4.04 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||||
| 2025-03-31 | -$0.93 10-Q · filed 2026-05-07 | -$1.77 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$2.95 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$4.73 derived: net income ÷ weighted average shares · filed 2026-05-07 | ||||
| 2024-12-31 | -$0.83 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$2.04 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$3.95 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$6.83 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | -$1.20 10-Q · filed 2025-11-06 | -$3.44 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$7.16 10-Q · filed 2025-11-06 | -$10.50 derived: net income ÷ weighted average shares · filed 2025-11-06 | ||||
| 2024-06-30 | -$4.34 10-Q · filed 2025-08-07 | -$12.97 10-Q · filed 2025-08-07 | -$19.01 derived: net income ÷ weighted average shares · filed 2025-08-07 | -$26.32 derived: net income ÷ weighted average shares · filed 2025-08-07 | ||||
| 2024-03-31 | -$10.97 10-Q · filed 2025-05-08 | -$0.15 10-Q · filed 2024-05-09 | -$16.95 derived: net income ÷ weighted average shares · filed 2025-05-08 | -$24.59 derived: net income ÷ weighted average shares · filed 2025-05-08 | -$33.08 derived: net income ÷ weighted average shares · filed 2025-05-08 | |||
| 2023-12-31 | -$5.89 derived: net income ÷ weighted average shares · filed 2025-03-20 | -$13.50 derived: net income ÷ weighted average shares · filed 2025-03-20 | -$21.91 derived: net income ÷ weighted average shares · filed 2025-03-20 | -$33.76 10-K · filed 2025-03-20 | $0.27 10-K · filed 2024-03-14 | |||
| 2023-09-30 | -$7.62 10-Q · filed 2024-11-12 | -$0.48 10-Q · filed 2023-11-09 | -$16.10 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$28.06 10-Q · filed 2024-11-12 | $0.47 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | -$8.51 10-Q · filed 2024-08-14 | $1.53 10-Q · filed 2023-08-10 | -$20.60 10-Q · filed 2024-08-14 | $0.96 10-Q · filed 2023-08-10 | ||||
| 2023-03-31 | -$0.57 10-Q · filed 2024-05-09 | |||||||
| 2022-12-31 | -$0.57 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$1.10 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$1.74 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$2.42 10-K · filed 2024-03-14 | ||||
| 2022-09-30 | -$0.52 10-Q · filed 2023-11-09 | -$1.17 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$1.85 10-Q · filed 2023-11-09 | |||||
| 2022-06-30 | -$0.64 10-Q · filed 2023-08-10 | -$1.32 10-Q · filed 2023-08-10 | ||||||
| 2022-03-31 | -$0.68 10-Q · filed 2023-05-11 | |||||||
| 2021-12-31 | -$2.78 10-K · filed 2023-03-23 | |||||||
| 2021-09-30 | -$0.75 10-Q · filed 2022-11-08 | -$2.13 10-Q · filed 2022-11-08 | ||||||
| 2021-06-30 | -$0.74 10-Q · filed 2022-08-09 | -$1.39 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |